deferiprone has been researched along with razoxane in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Clarke, JJ; Dunkel, VC; San, RH; Seifried, HE; Whittaker, P | 1 |
Barnabé, N; Hasinoff, BB; Venkataram, S; Zastre, JA | 1 |
2 other study(ies) available for deferiprone and razoxane
Article | Year |
---|---|
Genotoxicity of iron chelators in L5178Y mouse lymphoma cells.
Topics: Animals; Deferiprone; Edetic Acid; Iron Chelating Agents; Lymphoma; Mice; Mutagenicity Tests; Phenanthrolines; Pyridones; Razoxane; Tumor Cells, Cultured | 2001 |
Deferiprone protects against doxorubicin-induced myocyte cytotoxicity.
Topics: Animals; Animals, Newborn; Antineoplastic Agents; Cell Survival; Cells, Cultured; Deferiprone; Doxorubicin; Electron Spin Resonance Spectroscopy; Fluoresceins; Free Radicals; Indicators and Reagents; Iron; Iron Chelating Agents; L-Lactate Dehydrogenase; Myocytes, Cardiac; Oxidation-Reduction; Pyridones; Rats; Rats, Sprague-Dawley; Razoxane | 2002 |